Success Metrics

Clinical Success Rate
88.2%

Based on 30 completed trials

Completion Rate
88%(30/34)
Active Trials
23(28%)
Results Posted
30%(9 trials)
Terminated
4(5%)

Phase Distribution

Ph phase_1
9
11%
Ph phase_3
17
21%
Ph phase_4
14
17%
Ph phase_2
22
27%
Ph early_phase_1
4
5%
Ph not_applicable
12
15%

Phase Distribution

13

Early Stage

22

Mid Stage

31

Late Stage

Phase Distribution78 total trials
Early Phase 1First-in-human
4(5.1%)
Phase 1Safety & dosage
9(11.5%)
Phase 2Efficacy & side effects
22(28.2%)
Phase 3Large-scale testing
17(21.8%)
Phase 4Post-market surveillance
14(17.9%)
N/ANon-phased studies
12(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

30 of 39 finished

Non-Completion Rate

23.1%

9 ended early

Currently Active

23

trials recruiting

Total Trials

82

all time

Status Distribution
Active(28)
Completed(30)
Terminated(9)
Other(15)

Detailed Status

Completed30
Recruiting22
unknown14
Withdrawn5
Not yet recruiting4
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
82
Active
23
Success Rate
88.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (5.1%)
Phase 19 (11.5%)
Phase 222 (28.2%)
Phase 317 (21.8%)
Phase 414 (17.9%)
N/A12 (15.4%)

Trials by Status

unknown1417%
active_not_recruiting11%
completed3037%
not_yet_recruiting45%
suspended11%
enrolling_by_invitation11%
recruiting2227%
terminated45%
withdrawn56%

Recent Activity

Clinical Trials (82)

Showing 20 of 82 trialsScroll for more
NCT07569198Phase 2

Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

Not Yet Recruiting
NCT05962424Phase 1

HNC: Human Neural Circuits Electrophysiology During Cognition

Recruiting
NCT06496750Phase 2

Ketamine for Methamphetamine Use Disorder

Recruiting
NCT02543983Phase 2

Neurobiology of Suicide

Recruiting
NCT04763343Phase 3

Ketamine Treatment of Youth Suicide Attempters

Recruiting
NCT06402955Phase 2

Imaging Depression in Parkinson's Disease

Recruiting
NCT05437575Phase 3

Prehospital Analgesia INtervention Trial (PAIN)

Recruiting
NCT05004896Phase 2

Ketamine for Treatment-Resistant Bipolar Disorder

Completed
NCT05339074Phase 2

Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression

Completed
NCT05639322Phase 4

Psychotherapy for Ketamine's Enhanced Durability in Chronic Neuropathic Pain: A Randomized Controlled Pilot Trial

Completed
NCT04589208Phase 1

Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

Suspended
NCT06835504Phase 3

Morphine or Ketamine for Analgesia

Not Yet Recruiting
NCT05603104Phase 3

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting
NCT06062628Early Phase 1

Ketamine in Severe Traumatic Brain Injury

Recruiting
NCT06419439Phase 2

Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

Recruiting
NCT06480500Phase 2

i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

Recruiting
NCT04592809Phase 3

Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

Completed
NCT05378555Phase 3

Oral Ketamine for Treatment of Vaso-Occlusive Pain

Recruiting
NCT05973851Phase 3

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting
NCT06767358Phase 3

Ketamine Sedation in the ICU (KANINE) RCT

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
82